Ultrasound Study in Pregnant Women With Malaria

Malaria Clinical Trial

— UPS  

Official title:

Impact of Malaria Infection in Pregnancy on Fetal and Newborn Growth

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00840502
• Other study ID #: SMRU0801
• Status: Completed
• Start date: February 10, 2009
• Est. completion date: February 2018

Study information

• Verified date: September 2020
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Most of the neonatal deaths that occur worldwide every year are associated with low birth weight (LBW), caused by intrauterine growth restriction (IUGR) and/or preterm delivery. Accurate assessment of fetal growth and gestational age for timely identification and management of growth restriction are therefore public health priorities, especially in developing countries where 98% of all neonatal deaths occur. Every year, more than 50 million women become pregnant in malaria endemic regions. Malaria infection at any time during pregnancy reduces birthweight. However, little is known about the relationship between the timing of infection during pregnancy and the extent of the impact on birth weight. The mechanisms by which malaria causes LBW also remain unclear. Reduced placental blood flow, placental changes, red blood cell changes, severe anaemia and pro-inflammatory cytokines have all been implicated.

In this proposed, longitudinal, observational, minimal risk study, which will take place in SMRU antenatal clinics on the Thai-Burmese border, the effect of malaria infection during pregnancy on fetal growth will be determined. Women will be screened before 13+6 weeks of gestation and followed with regular ultrasound examinations during pregnancy. When a woman has a malaria infection an extra ultrasound scan will be done to measure growth retardation or placental blood flow changes. Bloodsamples will be taken to detect changes in red blood cell properties and putative markers of malaria infection. For this study the maximum amount of blood taken during pregnancy is 13 cc in an uninfected woman. For each malaria episode an additional 7 cc blood will be taken. After delivery a placenta and a cord sample will be taken to detect placental changes. The investigators aim to recruit four hundred pregnant women over the course of two years. This study involves minimal risk to participants as ultrasound examination is part of routine antenatal care in many countries in the world.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1887
• Est. completion date: February 2018
• Est. primary completion date: February 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Singleton viable pregnancy. If not detected at enrolment, multiple pregnancies will be excluded from the analysis.

• Age =18 years old.

• Willing and able to participate and comply with the study protocol and attend the SMRU ANCs regularly.

• EGA between 9+0 and 13+6 weeks by Ultrasound (CRL)

• Able to communicate in Burmese, Karen or English language

• written informed consent to participate in trial and follow consultation

Exclusion Criteria:

• Evidence of major congenital abnormality in the present pregnancy (e.g. anencephaly, omphalocele, hydrocephalus).

• Known chronic maternal illness.

• Thai national whose primary language is Thai

Related Conditions & MeSH terms

• Malaria
• Pregnant Women

Locations

Country	Name	City	State
Thailand	Shoklo Malaria Research Unit	Mae Sot	Tak

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ultrasound measurements		Up to birth
Secondary	Examination of all newborns		6 months post natal